Discovery of a Small Molecule Drug Candidate for Selective NKCC1 Inhibition in Brain Disorders
{{output}}
Aberrant expression ratio of Cl- transporters, NKCC1 and KCC2, is implicated in several brain conditions. NKCC1 inhibition by the FDA-approved diuretic drug, bumetanide, rescues core symptoms in rodent models and/or clinical trials with patients. However, bume... ...
